ERBB2 and breast cancer: In the past three decades, survival outcomes of patients with early breast cancer (EBC) have notably improved, mainly due to early detection of the disease and advances in adjuvant treatments, such as endocrine therapy (ET), chemotherapy (CT), and anti-HER2 therapy.